Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine is a paramagnetic chelate of gadolinium. After IV injection it distributes in the extracellular fluid and partially binds to hepatic proteins, shortening the T1 relaxation time of nearby water protons. This produces a higher signal on T1‑weighted MRI sequences, enhancing contrast between tissues.

The dose of Multihance is determined by the prescribing physician based on the specific MRI protocol, patient weight, and the organ system being examined. Dosing recommendations are provided in the product labeling and should be individualized for each patient.

The safety of gadobenate dimeglumine in pregnancy and lactation has not been established. It should be used only if the potential diagnostic benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the Multihance product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Compared with non‑specific gadolinium agents, gadobenate dimeglumine offers higher relaxivity and partial hepatic uptake, providing superior lesion detection in liver imaging. Its safety profile is similar to macrocyclic agents, but it remains a linear chelate, so renal function assessment is essential to mitigate the risk of nephrogenic systemic fibrosis.

Multihance should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. If the product reaches room temperature, it may be used within the time frame specified in the labeling.

Multihance is supplied as a sterile injection solution for intravenous use. It is typically injected as a bolus or power‑injector at a rate recommended by the imaging protocol, followed by a saline flush. Administration is performed by qualified healthcare personnel in a clinical setting.

The most serious risks include allergic reactions ranging from urticaria to anaphylaxis, and nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment. Rarely, severe hypotension, cardiac arrest, or pulmonary edema may occur. Prompt recognition and management are critical.

Multihance is contraindicated in patients with known hypersensitivity to gadobenate dimeglumine or any component of the formulation. It should be avoided in individuals with severe renal dysfunction (eGFR <30 mL/min/1.73 m²) due to the risk of NSF, and in patients with a history of severe allergic reactions to contrast media.